Print Page  |  Close Window

SEC Filings

424B5
PROTAGONIST THERAPEUTICS, INC filed this Form 424B5 on 08/07/2018
Entire Document
 

Table of Contents

CAPITALIZATION

        The following table sets forth our cash and cash equivalents and our capitalization as of March 31, 2018 on:

    an actual basis; and

    an as adjusted basis to give effect to the assumed issuance and sale by us of 2,750,000 shares of common stock in this offering at a price of $8.00 per share, after deducting estimated offering expenses payable by us.

        The following information should be read in conjunction with the consolidated financial statements and related notes incorporated by reference in this prospectus supplement and the accompanying prospectus. For more details on how you can obtain the documents incorporated by reference in this prospectus supplement and the accompanying prospectus, see "Where You Can Find More Information" and "Incorporation of Certain Information by Reference."

 
  As of
March 31, 2018
 
 
  Actual   As Adjusted  
 
  (in thousands,
except share and
per share data)

 

Cash and cash equivalents

  $ 69,577   $ 91,377  

Stockholders' equity:

             

Common stock, $0.00001 par value—authorized, 90,000,000 actual and as adjusted; issued and outstanding, 21,163,590 actual and 23,913,590 as adjusted

         

Additional paid-in capital

    223,904     245,704  

Accumulated other comprehensive loss

    (72 )   (72 )

Accumulated deficit

    (109,211 )   (109,211 )

Total stockholders' equity

    114,621     136,421  

Total capitalization

  $ 114,621   $ 136,421  

        The number of shares of our common stock to be outstanding after this offering is based on 21,163,590 shares of our common stock outstanding as of March 31, 2018 and excludes:

    2,984,522 shares of common stock issuable upon the exercise of stock options outstanding as of March 31, 2018, having weighted average exercise price of $12.67 per share;

    an aggregate of 664,068 shares of common stock, subject to increase on an annual basis, reserved for future issuance under our 2016 Equity Incentive Plan as of March 31, 2018;

    113,625 shares issuable upon vesting of outstanding restricted stock units, or RSUs; and

    454,660 shares of our common stock, subject to increase on an annual basis, reserved for future issuance under our 2016 Employee Stock Purchase Plan, as of March 31, 2018.

S-17